Here is how argenex SE (ARGX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

zacks.com - 2026-07-13 10:40:31

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-07-07 12:41:12

This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.

investors.com - 2026-07-06 13:10:18

Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now. Wells Fargo's Q3 Outlook 51 minutes ago Live Wells Fargo is betting on a strong summer for stocks, telling clients the Q3 sets up nicely for a rally before midterm election... Live Nasdaq Composite: Markets Kick Off H2 2026 on Cautious Note amid Chip Stock Profit Taking

247wallst.com - 2026-07-01 09:42:56

Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis plan for its ongoing Phase 3 Vyvgart study in myositis.

benzinga.com - 2026-06-25 13:57:56

Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myositis-focused R&D Day.

investors.com - 2026-06-24 10:29:19

argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcript

seekingalpha.com - 2026-06-24 01:32:09

Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.

marketbeat.com - 2026-06-12 07:07:03

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

investors.com - 2026-06-10 10:15:51

argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.

zacks.com - 2026-06-10 09:11:05

argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-10 01:22:11

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-06-08 12:41:08

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

zacks.com - 2026-06-08 10:01:33

argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

marketbeat.com - 2026-06-05 06:03:21

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following switch to biweekly dosing Cross-indication analysis of efgartigimod data across rheumatology studies underscores consistent safety profile in large patient population June 3, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) across autoimmune rheumatic diseases, including myositis and Sjogren's disease, to be presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3-6, 2026, in London, UK. “Our presentations at EULAR further support the rationale for targeting FcRn in autoimmune rheumatic diseases and underscore its potential to address significant unmet patient need,” said Luc Truyen, M.D.

globenewswire.com - 2026-06-03 01:00:00

May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on Tuesday, June 23, 2026, at 2:00pm ET.

globenewswire.com - 2026-05-28 01:00:00

May 27, 2026Amsterdam, the Netherlands - argenx (Euronext and Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June: William Blair 46th Annual Growth Stock Conference.

globenewswire.com - 2026-05-27 01:00:00

argenx (ARGX) is building a differentiated autoimmune platform, leveraging VYVGART's commercial success into a self-reinforcing growth engine. ARGX delivered 63% YoY sales growth in Q1 2026, maintains 30% operating margins, and funds pipeline expansion without near-term financing risk. The recent FDA approval of VYVGART for all adult gMG patients expands ARGX's addressable market and strengthens its competitive positioning.

seekingalpha.com - 2026-05-22 08:30:31

MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a

gurufocus.com - 2026-05-18 09:00:00

argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 15:40:42

Argenx SE – ADR (NASDAQ:ARGX) shares are up during Monday's session as the company celebrates a recent FDA approval for its drug, VYVGART, which adult patients with generalized myasthenia gravis can use.

benzinga.com - 2026-05-11 13:37:56

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients treated with VYVGART in the ADAPT SERON study experienced rapid, significant and sustained symptom improvements that continued with ongoing treatment Approval advances argenx's commitment to address the unique needs of every MG patient, delivering the broadest MG label to date May 8, 2026, 5:20 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for VYVGART® (efgartigimod alfa-fcab) and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG). The approved supplemental Biologics License Application (sBLA) expands VYVGART's indication to include all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative.

globenewswire.com - 2026-05-08 17:20:00

argenx SE (ARGX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 17:11:21

May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT.

globenewswire.com - 2026-05-06 16:30:00

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors' appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. “Karen has earned the full confidence of the Board of Directors and our shareholders,” said Tim Van Hauwermeiren, Chair of the Board of Directors.

globenewswire.com - 2026-05-06 16:01:00

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?

zacks.com - 2026-05-04 12:40:30

April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its first quarter 2026 financial results and provide a business update.

globenewswire.com - 2026-04-30 01:00:00

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of argenex SE (NASDAQ: ARGX) by 22.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,846 shares of the company's stock after purchasing an additional 2,018 shares during the quarter.

defenseworld.net - 2026-04-20 05:16:50

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. Presentations will also highlight new data for adimanebart in congenital myasthenic syndromes (CMS) and argenx's broader neuromuscular pipeline, including Phase 3 programs evaluating empasiprubart in CIDP.

globenewswire.com - 2026-04-18 01:00:00

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.

globenewswire.com - 2026-04-18 01:00:00